DDInter1592 DDInter1925
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is regulated by {v} (Gene) ADCK3
ADCK3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) regulates {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) regulates {v} (Gene) SATB1
SATB1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Vemurafenib (Compound)
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Vemurafenib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is regulated by ADCK3 (Gene) and ADCK3 (Gene) is upregulated by Vemurafenib (Compound)
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) regulates ABCC1 (Gene) and ABCC1 (Gene) is bound by Vemurafenib (Compound)
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Vemurafenib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) regulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)